Developing Transformational Medicines
Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, has created a revolutionary new way to design and develop oral small molecule therapies that are more potent, selective, durable and safer than currently available drugs. The Company has utilized its proprietary Tailored Covalency® technology to develop a portfolio of drug candidates that exhibit antibody-like specificity to benefit patients with autoimmune and inflammatory diseases and cancer. Its most advanced drug candidate, PRN1008, a reversible covalent BTK inhibitor, is in Phase 2 development for pemphigus vulgaris, an orphan autoimmune disease and PRN1371 is in Phase 1 for solid tumors. Since Principia began operations in 2011, its highly productive approach has led to the rapid advancement of PRN1008 and PRN1371 into the clinic and the creation of a growing portfolio of programs for autoimmune and inflammatory diseases.
Powered by Tailored Covalency®
Principia Biopharma challenges traditional drug discovery by utilizing its proprietary technology to discover new medicines that combine the dosing convenience of an oral small molecule drug with the specificity of an antibody.
Principia’s leadership team includes biotechnology executives and veteran drug developers who are passionate about creating a new way to develop better small molecule drugs.
Board of Directors